Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5081237
Max Phase: Preclinical
Molecular Formula: C28H43NO41S5
Molecular Weight: 1209.95
Molecule Type: Unknown
Associated Items:
ID: ALA5081237
Max Phase: Preclinical
Molecular Formula: C28H43NO41S5
Molecular Weight: 1209.95
Molecule Type: Unknown
Associated Items:
Canonical SMILES: NCCOCCO[C@@H]1O[C@@H](C(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@@H]3O[C@@H](C(=O)O)[C@@H](O[C@@H]4O[C@@H](C(=O)O)[C@@H](OS(=O)(=O)O)[C@H](O)[C@H]4OS(=O)(=O)O)[C@H](O)[C@H]3OS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1OS(=O)(=O)O
Standard InChI: InChI=1S/C28H43NO41S5/c29-1-2-57-3-4-58-25-13(67-72(45,46)47)5(30)9(17(62-25)21(34)35)59-26-14(68-73(48,49)50)6(31)10(18(63-26)22(36)37)60-27-15(69-74(51,52)53)7(32)11(19(64-27)23(38)39)61-28-16(70-75(54,55)56)8(33)12(66-71(42,43)44)20(65-28)24(40)41/h5-20,25-28,30-33H,1-4,29H2,(H,34,35)(H,36,37)(H,38,39)(H,40,41)(H,42,43,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56)/t5-,6-,7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17+,18+,19+,20+,25+,26+,27+,28+/m0/s1
Standard InChI Key: XTAYRTOFKVNHSI-WWVMWJLHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1209.95 | Molecular Weight (Monoisotopic): 1208.9914 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Shanthamurthy CD, Leviatan Ben-Arye S, Kumar NV, Yehuda S, Amon R, Woods RJ, Padler-Karavani V, Kikkeri R.. (2021) Heparan Sulfate Mimetics Differentially Affect Homologous Chemokines and Attenuate Cancer Development., 64 (6.0): [PMID:33683903] [10.1021/acs.jmedchem.0c01800] |
Source(1):